Keros Therapeutics (KROS) News Today $15.74 +0.57 (+3.76%) As of 03:33 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock KROS Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Keros Therapeutics: Orphan Drug Win For DMD Candidate A Small Step On Right PathAugust 21 at 5:12 PM | seekingalpha.comKeros Therapeutics, Inc.: Keros Announces U.S. FDA Orphan Drug Designation Granted to KER-065 for the Treatment of Duchenne Muscular DystrophyAugust 21 at 11:16 AM | finanznachrichten.deADAR1 Sends Open Letter to Keros Board of Directors Urging the Board to Engage Constructively on Strategy, Capital Allocation and Board RefreshmentAugust 21 at 8:30 AM | prnewswire.comKeros Therapeutics granted Orphan Drug designation for KER-065 in DMDAugust 21 at 2:14 AM | msn.comKeros Therapeutics Receives FDA Orphan Drug Designation for KER-065 in Duchenne Muscular Dystrophy TreatmentAugust 20 at 10:11 AM | quiverquant.comQKeros Announces U.S. FDA Orphan Drug Designation Granted to KER-065 for the Treatment of Duchenne Muscular DystrophyAugust 20 at 10:03 AM | globenewswire.comKeros Therapeutics’ treatment of Duchenne MD granted FDA orphan designationAugust 19 at 9:58 PM | msn.comConnor Clark & Lunn Investment Management Ltd. Has $1.31 Million Stake in Keros Therapeutics, Inc. (NASDAQ:KROS)August 18, 2025 | marketbeat.com40,245 Shares in Keros Therapeutics, Inc. (NASDAQ:KROS) Purchased by Tejara Capital LtdAugust 17, 2025 | marketbeat.comKeros Therapeutics Announces Strategic Realignment and Leadership ChangesAugust 15, 2025 | theglobeandmail.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: AMN Healthcare Services (AMN), Keros Therapeutics (KROS) and Evolent Health (EVH)August 11, 2025 | theglobeandmail.comKeros Therapeutics (NASDAQ:KROS) Price Target Cut to $20.00 by Analysts at HC WainwrightAugust 11, 2025 | americanbankingnews.comWilliam Blair Cuts Earnings Estimates for Keros TherapeuticsAugust 11, 2025 | americanbankingnews.comLeerink Partnrs Has Negative Estimate for KROS Q3 EarningsAugust 11, 2025 | marketbeat.comWilliam Blair Predicts Lower Earnings for Keros TherapeuticsAugust 11, 2025 | marketbeat.comHC Wainwright Cuts Keros Therapeutics (NASDAQ:KROS) Price Target to $20.00August 9, 2025 | marketbeat.comXTX Topco Ltd Acquires New Position in Keros Therapeutics, Inc. (NASDAQ:KROS)August 9, 2025 | marketbeat.comKeros to Exclusively Prioritize the Clinical Advancement of KER-065August 6, 2025 | globenewswire.comKeros Therapeutics Reports Second Quarter 2025 Financial ResultsAugust 6, 2025 | globenewswire.comFederated Hermes Inc. Grows Position in Keros Therapeutics, Inc. (NASDAQ:KROS)August 3, 2025 | marketbeat.comKeros Therapeutics (KROS) Projected to Post Earnings on WednesdayJuly 31, 2025 | marketbeat.comKeros Therapeutics, Inc. (NASDAQ:KROS) Given Consensus Rating of "Moderate Buy" by AnalystsJuly 31, 2025 | marketbeat.comCorton Capital Inc. Makes New $186,000 Investment in Keros Therapeutics, Inc. (NASDAQ:KROS)July 28, 2025 | marketbeat.comKeros Therapeutics Announces the First Patient Dosing in the Phase 3 RENEW Clinical Trial of ElriterceptJuly 17, 2025 | globenewswire.comKeros Therapeutics, Inc. (NASDAQ:KROS) Receives Consensus Rating of "Moderate Buy" from BrokeragesJuly 6, 2025 | marketbeat.comB of A Securities Downgrades Keros Therapeutics (KROS)June 11, 2025 | msn.comKeros Therapeutics, Inc. (NASDAQ:KROS) Receives Consensus Recommendation of "Moderate Buy" from AnalystsJune 11, 2025 | marketbeat.comKeros Therapeutics' Quiet Near-Term Outlook Overshadows Pipeline Potential: AnalystJune 10, 2025 | uk.finance.yahoo.com3KROS : Keros Therapeutics' Quiet Near-Term Outlook Overshadows Pipeline...June 10, 2025 | benzinga.comKeros Therapeutics (NASDAQ:KROS) Rating Lowered to "Neutral" at Bank of AmericaJune 10, 2025 | marketbeat.comKeros Therapeutics, Inc.: Keros Announces Return of $375 Million in Excess Capital to StockholdersJune 9, 2025 | finanznachrichten.deADAR1 Issues Statement on Keros Therapeutics' Troubling 2025 Director Election Results and Insufficient Capital Return ProposalJune 9, 2025 | prnewswire.comKeros Therapeutics (NASDAQ:KROS) Shares Gap Down - Here's What HappenedJune 9, 2025 | marketbeat.comKeros Announces Return of $375 Million in Excess Capital to StockholdersJune 9, 2025 | globenewswire.comKeros Therapeutics, Inc. (NASDAQ:KROS) Stock Position Boosted by Two Sigma Investments LPJune 9, 2025 | marketbeat.comAnalysts Are Bullish on Top Healthcare Stocks: Icon (ICLR), Keros Therapeutics (KROS)June 7, 2025 | theglobeandmail.comKeros Therapeutics Announces Participation at Goldman Sachs 46th Annual Global Healthcare ConferenceJune 6, 2025 | globenewswire.comNuveen Asset Management LLC Reduces Stock Position in Keros Therapeutics, Inc. (NASDAQ:KROS)June 5, 2025 | marketbeat.comKeros Therapeutics' (KROS) "Neutral" Rating Reaffirmed at WedbushMay 31, 2025 | marketbeat.comKeros Therapeutics Discontinues Cibotercept Development in PAH and Announces Corporate RestructuringMay 30, 2025 | nasdaq.comKeros Therapeutics (NASDAQ:KROS) Trading Down 3.9% - Here's What HappenedMay 30, 2025 | marketbeat.comD. E. Shaw & Co. Inc. Sells 174,189 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS)May 30, 2025 | marketbeat.comKeros Therapeutics, Inc. (KROS) Halts PAH Drug Development After Safety Concerns in TROPOS TrialMay 29, 2025 | insidermonkey.comKeros Therapeutics, Inc.: Keros Therapeutics Announces TROPOS Topline Data and Corporate RestructuringMay 29, 2025 | finanznachrichten.deKeros Cutting 45% of Staff, Ending Development of Cibotercept in PAHMay 29, 2025 | marketwatch.comKeros falls after discontinuation of hypertension treatment trialMay 29, 2025 | msn.comKeros Therapeutics Announces TROPOS Topline Data and Corporate RestructuringMay 29, 2025 | globenewswire.comLeading Independent Proxy Advisory Firm Glass Lewis Recommends Stockholders Vote “FOR” All of Keros’ Director NomineesMay 27, 2025 | finance.yahoo.comLeading Independent Proxy Advisory Firm Glass Lewis Recommends Stockholders Vote “FOR” All of Keros' Director NomineesMay 27, 2025 | globenewswire.comTFG Asset Management GP Ltd Invests $1.63 Million in Keros Therapeutics, Inc. (NASDAQ:KROS)May 27, 2025 | marketbeat.com Get Keros Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KROS and its competitors with MarketBeat's FREE daily newsletter. Email Address KROS Media Mentions By Week KROS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. KROS News Sentiment▼0.960.54▲Average Medical News Sentiment KROS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. KROS Articles This Week▼106▲KROS Articles Average Week Get Keros Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KROS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Recursion Pharmaceuticals News Tarsus Pharmaceuticals News Belite Bio News Ocular Therapeutix News IDEAYA Biosciences News Agios Pharmaceuticals News Harmony Biosciences News Denali Therapeutics News Disc Medicine News Mesoblast News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:KROS) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersSilver’s Still Under $35… For Now.Silver is trading around $33—but insiders are betting on a $70 breakout by year’s end. With supply shrinkin...GoldenCrest Metals | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredBREAKING: The House just passed 3 pro-crypto bills!The “top secret” DeFi play Our #1 Coin Report reveals which protocol is building this institutional bridge...Crypto 101 Media | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Keros Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Keros Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access